Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Open-Label, Allopurinol-Controlled, Multicenter Study With Two Optional Extensions to Evaluate the Safety and Efficacy of AR882 Alone or in Combination With Allopurinol in Tophaceous Gout Patients

NCT05253833 is registered in ClinicalTrials.gov with Arthrosi Therapeutics as lead sponsor.

NCT NCT05253833
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05253833 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Open-Label, Allopurinol-Controlled, Multicenter Study With Two Optional Extensions to Evaluate the Safety and Efficacy of AR882 Alone or in Combination With Allopurinol in Tophaceous Gout Patients
Lead sponsor
Arthrosi Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
August 12, 2022
Completion date
October 28, 2024
Enrollment
42 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, gouty, gout, gout chronic, hyperuricemia